BAJAJ BROKING
Torrent Pharmaceuticals reported consolidated revenue of ₹2,889 crore and a PAT of ₹453 crore for Q2 FY24-25, representing a growth of 17% in profit. Detailed insights into segment-wise performances and management commentary are provided below.
Torrent Pharmaceuticals Limited posted its consolidated financial results for Q2 FY24-25, showcasing robust growth. The company reported consolidated revenue of ₹2,889 crore and Profit After Tax (PAT) of ₹453 crore, reflecting a year-on-year growth of 17%.
Torrent Pharma’s quarterly performance shows consistent growth across various metrics, driven by strong market traction in branded markets. Here are some key highlights.
Metric | Q2 FY24-25 | Q2 FY23-24 | % Change |
Revenue from Operations | ₹2,889 Cr | ₹2,660 Cr | 9% |
Profit After Tax (PAT) | ₹453 Cr | ₹386 Cr | 17% |
EBITDA | ₹939 Cr | ₹825 Cr | 14% |
EBITDA Margin | 32.50% | 31% | 1.50% |
Gross Margin | 76.50% | 75% | 1.50% |
R&D Spend | ₹145 Cr | ₹132 Cr | 10% |
Torrent Pharma's performance are at par with sector expectations, with its strong presence in chronic therapies driving consistent growth in key markets such as India, Brazil, and Germany. The pharmaceutical sector anticipates continued recovery, and Torrent Pharma is well-positioned to capitalize on this momentum.
Torrent Pharma's management highlighted the company's strong Q2 performance, attributing it to continued traction in branded markets and operational efficiencies. They remain confident in achieving their year-end targets despite the scheduled maintenance shutdown in the insulin segment, which will see recovery in Q4 FY25.
Check out Torrent Pharma's past performances in previous quarters and financial years.
Torrent Pharma’s Q2 FY24-25 results demonstrate consistent growth across all key markets, with a revenue of ₹2,889 crore and PAT of ₹453 crore, a 17% increase year-on-year. With its strong focus on branded markets and operational efficiencies, the company remains on track to achieve its growth targets for the year.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading